News

The Helmholtz Institute for Translational AngioCardioScience in Mannheim/Heidelberg has appointed vascular biologist Karina Yaniv from the Weizmann Institute as its new Scientific Director. Yaniv will bridge research across institutes to fast-track therapies for cardiovascular disease.

Families, researchers, and clinicians will gather in Berlin to share knowledge and build momentum toward therapies for NEDAMSS, a rare neurodevelopmental disorder. Jakob Metzger, Group Leader of the Quantitative Stem Cell Biology lab explains why this day matters and what participants can expect.

Joint press release by the Max Delbrück Center and the Helmholtz Centre for Infection Research One...

The founding director of the Max Delbrück Center, physician and pharmacologist Detlev Ganten, celebrates his 85th birthday on March 28, 2026. Without his commitment, our research center would not exist as we know it today. Once again, we say thank you and offer our heartfelt congratulations!

In aggressive lymphomas, inflammatory messengers reprogram the “conductors” of the immune system, causing lymph node structure to collapse. A team led by Simon Haas describes in “Nature Cancer” this process for the first time using single-cell and spatial analyses.

The Max Delbrück Center’s Global Fellow Postdoctoral Program aims to establish a structure to foster greater interdisciplinary research among different labs. Our first winners of the three-year fellowship, who will be joining us as members of multiple labs, start this month.

At the Einstein Center for Early Disease Interception, researchers from twelve Berlin institutions will be pooling their expertise to explore new approaches to prevention, long before symptoms appear, and bring them quickly into practice. The center opens today with a ceremony.

Researchers at the Max Delbrück Center and Charité – Universitätsmedizin Berlin show that adipose tissue amplifies gut inflammation in Crohn’s disease. The study, published in the “Journal of Clinical Investigation,” also reveals how genetic changes in immune cells may contribute to the disease.

Checkpoint inhibitors help fight cancer but increase the risk of heart disease. An interdisciplinary team, including researchers from the Max Delbrück Center, is investigating how the therapy can be made safer. The Hector Foundation is supporting the project with €1.3 million.

Researchers have uncovered the molecular details of how ancient viral DNA controls a gene linked to preeclampsia. The study, published in “Genome Biology,” builds on previous research and may lead to a diagnostic test to identify preeclampsia risk much earlier.